Tue, Sep 16, 2014, 8:35 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Inovio Pharmaceuticals, Inc. Message Board

  • deliveryman61 deliveryman61 May 23, 2013 9:18 AM Flag

    For the New People/Longs...HIV Results pending 'Peer Review'

     

    We submitted Our Phase 1 Results for peer review in early February. Silence since...If you Know the History of attempted HIV Vacines and Therapuetics to date...You would then Know that FEW make it thru phase 1 due to failure or causing Death...We do NOT have Safety issues as we Use NO Drugs...So....we Await the Results that COULD potentailly LAUNCH this Company to Stardom Status....TRUE...This Virus has thwarted ALL efforts 'til now for a Therapuetic.. we tested 12 HIV Positive volunteers for Our Therapuetic value...BUT we ALSO Tested 48 Healthy Volunteers with our Vaccine to prevent HIV...Ebola and Smallpox approach a 100% Mortality Rate...WE WERE 100% Successful as a VACCINE Against BOTH...Monkeys for Smallpox...Mice for Ebola thusfar...think our HIV Vaccine could 'Shock the World'???...Worth a 'play' at the VERY Least...EOM

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Investors of INO expected news for flu and HIV vaccines in the Q2/2013. Instead, the got until today:
      The expected flu results, positive.
      Preclinical results for some kinds of viral hemorrhagic fevers, very positive.
      Grant from US army for a new electroporation device.
      Two ViE awards.

      I think in June wil see the HIV results also. I hope the stock will drop a few cents lower so I can buy back my trading shares at the price I sold them. If not, I will make a new buy because as we move forward, only good news will come.

      Sentiment: Strong Buy

 
INO
10.50-0.01(-0.10%)Sep 16 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.